Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Status:
Completed
Trial end date:
2016-01-21
Target enrollment:
Participant gender:
Summary
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a
(PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus
(HBV) co-infected with hepatitis delta virus (HDV).